Shelly Seward

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

Raffit Hassan, George R. Blumenschein, Kathleen N. Moore et al. · Journal of Clinical Oncology · 2020 · 164 citations · Full text

Phase 1 dose‐escalation study of mirvetuximab soravtansine (<scp>IMGN853</scp>), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors

Kathleen N. Moore, Hossein Borghaei, David M. O’Malley et al. · Cancer · 2017 · 133 citations · Full text

Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine

Lainie P. Martin, Jason Konner, Kathleen N. Moore et al. · Gynecologic Oncology · 2017 · 125 citations · Full text

Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells

Sanjeev Kumar, Christopher S. Bryant, Sreedhar Chamala et al. · Molecular Cancer · 2009 · 92 citations · Full text

Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells

Christopher S. Bryant, Sanjeev Kumar, Sreedhar Chamala et al. · Molecular Cancer · 2010 · 72 citations · Full text